Side-by-side · Research reference
RetatrutidevsVilon
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED10/41 cited
BAnimal-StrongHUMAN-REVIEWED13/49 cited
Retatrutide
Triple-receptor agonist · Phase 3
SQ · Abdomen · Once weekly
Vilon
Khavinson Bioregulator · Dipeptide
Literature lacks standardised clinical route
01Mechanism of Action
Parameter
Retatrutide
Vilon
Primary target
GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023
Immune cell differentiation pathways, chromatin modification
Pathway
Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023
Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)
Downstream effect
Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023
Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011Khavinson 2002Lezhava 2023
Feedback intact?
—
Unknown — no HPA/HPG axis data
Origin
Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023
Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997
Antibody development
—
—
02Dosage Protocols
Parameter
Retatrutide
Vilon
Standard dose
12 mg / week (max efficacy)Jastreboff 2023
Phase 2 trial dose. Phase 3 dosing TBD.
No clinical standard — literature lacks human dosing
Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.
Frequency
Once weekly
Unknown — literature does not specify chronic administration protocols
Titration schedule
2 mg → 4 mg → 8 mg → 12 mg over 16 weeks
—
Duration
Indefinite for chronic indication (presumed)
Not characterised in humans
Reconstitution
Investigational; not commercially available
—
Timing
Any time of day
—
Half-life
~6 days (estimated from class)
Not published — dipeptides typically <10 min plasma t½
Animal model dose
—
In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)
Not translatable to human mg/kg without pharmacokinetic data.
Route
—
Likely SQ or oral (Khavinson school uses both); no published ROA validation
04Side Effects & Safety
Parameter
Retatrutide
Vilon
Glucose handling
Glycemic improvement; rare hyperglycemia from glucagon component
—
Pancreatitis risk
Class warning
—
Thyroid C-cell tumours
Class warning (presumed)
—
Pregnancy / OB
Avoid (insufficient data)
—
Human safety data
—
Absent from PubMed-indexed literature
Theoretical risk
—
Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)
Antibody formation
—
Not reported; dipeptides generally low immunogenicity
Animal models
—
No adverse effects noted in mouse thymocyte or pineal lymphoid cultures
Absolute Contraindications
Retatrutide
- ·MTC personal or family history (presumed class effect)
- ·Pregnancy / breastfeeding
Vilon
- ·Active autoimmune disease (theoretical — no clinical data)
Relative Contraindications
Retatrutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe cardiovascular disease (HR signal)
Vilon
- ·Pregnancy / lactation (no safety data)
- ·Acute infection with cytokine storm risk (immune modulation unknown)
05Administration Protocol
Parameter
Retatrutide
Vilon
1. Reconstitution
Investigational peptide. Research vials reconstituted with bacteriostatic water per label.
No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.
2. Injection site
SQ — abdomen, thigh, or upper arm. Rotate weekly.
Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.
3. Timing
Once weekly, same day.
Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.
4. Storage
Refrigerate 2–8 °C. Light-protected.
Likely lyophilised powder, refrigerated. Reconstitution protocols not published.
5. Needle
27–31G, 4–8 mm insulin syringe.
—
06Stack Synergy
Retatrutide
— no documented stacks
Vilon
+ Epitalon
ModerateBoth are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.
- Vilon
- Empirical — no standard
- Epitalon
- Empirical — often 10 mg cycles
- Frequency
- Sequential or concurrent (literature ambiguous)
- Primary benefit
- Multi-system aging modulation (immune + pineal/circadian)
+ Thymalin
WeakThymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.
- Vilon
- No standard
- Thymalin
- 10–100 mg IM (polypeptide complex)
- Primary benefit
- Redundant — both target T-cell differentiation